Cellular targets for influenza drugs.
作者信息
Min Ji-Young, Subbarao Kanta
出版信息
Nat Biotechnol. 2010 Mar;28(3):239-40. doi: 10.1038/nbt0310-239.
Abstract
摘要
相似文献
1
Cellular targets for influenza drugs.
Nat Biotechnol. 2010 Mar;28(3):239-40. doi: 10.1038/nbt0310-239.
2
Polycation-mediated delivery of siRNAs for prophylaxis and treatment of influenza virus infection.
Expert Opin Biol Ther. 2005 Apr;5(4):495-505. doi: 10.1517/14712598.5.4.495.
3
[The potential of synthetic small interfering RNA-based antiviral drugs for influenza treatment].
Vopr Virusol. 2020 Sep 16;65(4):182-190. doi: 10.36233/0507-4088-2020-65-4-182-190.
4
Network-Guided Discovery of Influenza Virus Replication Host Factors.
mBio. 2018 Dec 18;9(6):e02002-18. doi: 10.1128/mBio.02002-18.
5
Influenza A: New Therapeutic Targets for a Deadly Disease.
Arch Bronconeumol (Engl Ed). 2019 Jun;55(6):295-296. doi: 10.1016/j.arbres.2018.09.020. Epub 2018 Nov 5.
6
Efficient Inhibition of Avian and Seasonal Influenza A Viruses by a Virus-Specific Dicer-Substrate Small Interfering RNA Swarm in Human Monocyte-Derived Macrophages and Dendritic Cells.
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01916-18. Print 2019 Feb 15.
7
A Drosophila model for genetic analysis of influenza viral/host interactions.
Genetics. 2011 Oct;189(2):495-506. doi: 10.1534/genetics.111.132290. Epub 2011 Jul 20.
8
The Immunomodulatory CEA Cell Adhesion Molecule 6 (CEACAM6/CD66c) Is a Protein Receptor for the Influenza a Virus.
Viruses. 2021 Apr 21;13(5):726. doi: 10.3390/v13050726.
9
Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
Front Immunol. 2019 Jan 29;10:60. doi: 10.3389/fimmu.2019.00060. eCollection 2019.
10
Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.
Antimicrob Agents Chemother. 2013 Jan;57(1):475-83. doi: 10.1128/AAC.01532-12. Epub 2012 Nov 5.
引用本文的文献
1
Targeting Key Stages of the Viral Entry and Life Cycle: A Comprehensive Overview of the Mechanisms of Antiviral Actions.
Methods Mol Biol. 2025;2927:259-286. doi: 10.1007/978-1-0716-4546-8_15.
2
Nuclear magnetic resonance reveals a two hairpin equilibrium near the 3'-splice site of influenza A segment 7 mRNA that can be shifted by oligonucleotides.
RNA. 2022 Apr;28(4):508-522. doi: 10.1261/rna.078951.121. Epub 2022 Jan 4.
3
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Protein Cell. 2020 Oct;11(10):723-739. doi: 10.1007/s13238-020-00768-w. Epub 2020 Aug 4.
4
Lack of selective resistance of influenza A virus in presence of host-targeted antiviral, UV-4B.
Sci Rep. 2019 May 16;9(1):7484. doi: 10.1038/s41598-019-43030-y.
5
In vivo analysis of influenza A mRNA secondary structures identifies critical regulatory motifs.
Nucleic Acids Res. 2019 Jul 26;47(13):7003-7017. doi: 10.1093/nar/gkz318.
6
Stimulation of alpha2-adrenergic receptors impairs influenza virus infection.
Sci Rep. 2018 Mar 15;8(1):4631. doi: 10.1038/s41598-018-22927-0.
7
Acid phosphatase 2 (ACP2) is required for membrane fusion during influenza virus entry.
Sci Rep. 2017 Mar 8;7:43893. doi: 10.1038/srep43893.
8
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82. doi: 10.1128/AAC.04623-14. Epub 2014 Dec 29.
9
EHFPI: a database and analysis resource of essential host factors for pathogenic infection.
Nucleic Acids Res. 2015 Jan;43(Database issue):D946-55. doi: 10.1093/nar/gku1086. Epub 2014 Nov 20.
10
Targeting cell division cycle 25 homolog B to regulate influenza virus replication.
J Virol. 2013 Dec;87(24):13775-84. doi: 10.1128/JVI.01509-13. Epub 2013 Oct 9.
本文引用的文献
1
Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication.
Nature. 2010 Feb 11;463(7282):818-22. doi: 10.1038/nature08760. Epub 2010 Jan 17.
2
A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection.
Cell. 2009 Dec 24;139(7):1255-67. doi: 10.1016/j.cell.2009.12.018.
3
The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.
Cell. 2009 Dec 24;139(7):1243-54. doi: 10.1016/j.cell.2009.12.017.
4
Human host factors required for influenza virus replication.
Nature. 2010 Feb 11;463(7282):813-7. doi: 10.1038/nature08699.
5
CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission.
J Infect Dis. 2010 Jan 15;201(2):178-85. doi: 10.1086/649426.
6
A genome-wide genetic screen for host factors required for hepatitis C virus propagation.
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16410-5. doi: 10.1073/pnas.0907439106. Epub 2009 Aug 27.
7
Genome-scale RNAi screen for host factors required for HIV replication.
Cell Host Microbe. 2008 Nov 13;4(5):495-504. doi: 10.1016/j.chom.2008.10.004. Epub 2008 Oct 30.
8
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication.
Cell. 2008 Oct 3;135(1):49-60. doi: 10.1016/j.cell.2008.07.032.
9
RNA interference screen for human genes associated with West Nile virus infection.
Nature. 2008 Sep 11;455(7210):242-5. doi: 10.1038/nature07207.
10
Drosophila RNAi screen identifies host genes important for influenza virus replication.
Nature. 2008 Aug 14;454(7206):890-3. doi: 10.1038/nature07151. Epub 2008 Jul 9.
Zotero 插件